4basebio PLC
88Q
Company Profile
Business description
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Contact
25 Norman Way
Over
CambridgeCB24 5QE
GBRT: +44 1223967943
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
110
Stocks News & Analysis
stocks
Bapcor earnings: Under review amid sharply lower profits and a massively dilutive equity raise
Our view of results.
stocks
Earnings winners: WOW, WTC and FMG set the tone
The ASX companies that closed out earnings season with a bang.
stocks
Do dividends build or limit wealth creation?
In this episode of Investing Compass, we talk to James Gruber about why he dislikes dividend stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,435.60 | 15.10 | 0.16% |
| CAC 40 | 8,580.75 | 40.18 | -0.47% |
| DAX 40 | 25,284.26 | 4.76 | -0.02% |
| Dow JONES (US) | 48,977.92 | 521.28 | -1.05% |
| FTSE 100 | 10,910.55 | 63.85 | 0.59% |
| HKSE | 26,630.54 | 249.52 | 0.95% |
| NASDAQ | 22,668.21 | 210.17 | -0.92% |
| Nikkei 225 | 58,850.27 | 96.88 | 0.16% |
| NZX 50 Index | 13,722.97 | 52.26 | 0.38% |
| S&P 500 | 6,878.88 | 29.98 | -0.43% |
| S&P/ASX 200 | 9,198.60 | 16.90 | 0.18% |
| SSE Composite Index | 4,162.88 | 16.25 | 0.39% |